Recent News

• 11.13.2025 - Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.06.2025 - Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
• 10.27.2025 - Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
• 10.14.2025 - Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
• 10.07.2025 - Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
• 10.06.2025 - Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
• 09.30.2025 - Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
• 09.24.2025 - Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
• 09.11.2025 - Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
• 09.09.2025 - Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Recent Filings

• 10.20.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 10.10.2025 - 8-K Current report
• 10.06.2025 - 8-K Current report
• 10.06.2025 - EX-99.1 EX-99.1
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]